Joanna Golebiowska

Joanna Golebiowska

Auto-generated profile, based on publicly available information

Joanna Golebiowska

Behavioral Neuroscience and Drug Development, Maj Institute of Pharmacology, Polish Academy of Sciences, Kraków, Poland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2015 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
RRRafał Ryguła
Rafał Ryguła
JGJoanna Golebiowska
Joanna Golebiowska
JKJakub Kregiel
Jakub Kregiel
JKJakub Kubik
Jakub Kubik
PPPiotr Popik
Piotr Popik
In humans, optimism is a cognitive construct related to motivation; optimists exert effort, whereas pessimists disengage from effort. In this study, using a recently developed ambiguous-cue interpretation (ACI) paradigm we took the unique opportunity to investigate whether ‘optimism’ as a trait is correlated with motivation in rodents. In a series of ACI tests (cognitive bias screening, CBS), we identified rats displaying ‘pessimistic’ and ‘optimistic’ traits. Subsequently, we investigated the trait differences in the motivation of these rats to gain reward and to avoid punishment using a progressive ratio schedule of reinforcement paradigm. Although ‘optimistic’ and ‘pessimistic’ animals did not differ in their motivation to avoid punishment, the ‘optimistic’ rats were significantly more motivated to gain reward than their ‘pessimistic’ conspecifics. For the first time, we showed an association between cognitive judgment bias and motivation in an animal model. Because both investigated processes are closely related to mental health and wellbeing, our results may be valuable for preclinical modeling of many psychiatric disorders.

18 November 2015 in Neurotoxicity Research
Verified
Journal Article
Open access
PDF file
UDUrszula Doboszewska
Urszula Doboszewska
Bernadeta SzewczykBernadeta Szewczyk
Bernadeta Szewczyk
MSMagdalena Sowa-Kućma
Magdalena Sowa-Kućma
KNKarolina Noworyta
Karolina Noworyta
Paulina MisztakPaulina Misztak
Paulina Misztak
GNGabriel Nowak
Gabriel Nowak
Our previous study showed that dietary zinc restriction induces depression-like behavior with concomitant up-regulation of the N-methyl-d-aspartate receptor (NMDAR). Because metal ions, oxidative stress, and inflammation are involved in depression/NMDAR function, in the present study, bio-elements (zinc, copper, iron, magnesium, and calcium), oxidative (thiobarbituric acid-reactive substances; protein carbonyl content), and inflammatory (IL-1α, IL-1β) factors were measured in serum, hippocampus (Hp), and prefrontal cortex (PFC) of male Sprague–Dawley rats subjected to a zinc-adequate (ZnA) (50 mg Zn/kg) or a zinc-deficient (ZnD) (3 mg Zn/kg) diet for 4 or 6 weeks. Both periods of dietary zinc restriction reduced serum zinc and increased serum iron levels. At 4 weeks, lowered zinc level in the PFC and Hp as well as lowered iron level in the PFC of the ZnD rats was observed. At 6 weeks, however, iron level was increased in the PFC of these rats. Although at 6 weeks zinc level in the PFC did not differ between the ZnA and ZnD rats, extracellular zinc concentration after 100 mM KCl stimulation was reduced in the PFC of the ZnD rats and was accompanied by increased extracellular iron and glutamate levels (as measured by the in vivo microdialysis). The examined oxidative and inflammatory parameters were generally enhanced in the tissue of the ZnD animals. The obtained data suggest dynamic redistribution of bio-elements and enhancement of oxidative/inflammatory parameters after dietary zinc restriction, which may have a link with depression-like behavior/NMDAR function/neurodegeneration.

2 March 2022 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
PPPiotr Popik
Piotr Popik
AHAdam Hogendorf
Adam Hogendorf
RBRyszard Bugno
Ryszard Bugno
SKShaun Khoo
Shaun Khoo
PZPaweł Zajdel
Paweł Zajdel
JGJoanna Golebiowska
Joanna Golebiowska
Rationale: Ketamine and psilocybin belong to the rapid-acting antidepressants but they also produce psychotomimetic effects including timing distortion. It is currently debatable whether these are essential for their therapeutic actions. As depressed patients report that the “time is dragging,” we hypothesized that ketamine and psilocybin-like compounds may produce an opposite effect, i.e., time underestimation, purportedly contributing to their therapeutic properties. Objectives: Timing was tested following administration of (R)- and (S)-ketamine, and psilocybin, psilocin, and norpsilocin in the discrete-trial temporal discrimination task (TDT) in male rats. Timing related to premature responses, and cognitive and unspecific effects of compounds were tested in the 5-choice serial reaction time task (5-CSRTT) in the standard 1-s, and “easier” 2-s stimulus duration conditions, as well as in the vITI variant promoting impulsive responses. Results: (S)-ketamine (15 but not 3.75 or 7.5 mg/kg) shifted psychometric curve to the right in TDT and reduced premature responses in 5-CSRTT, suggesting expected time underestimation, but it also decreased the accuracy of temporal discrimination and increased response and reward latencies, decreased correct responses, and increased incorrect responses. While (R)-ketamine did not affect timing and produced no unspecific actions, it reduced incorrect responses in TDT and increased accuracy in 5-CSRTT, suggesting pro-cognitive effects. Psilocin and psilocybin produced mainly unspecific effects in both tasks, while norpsilocin showed no effects. Conclusions: Time underestimation produced by (S)-ketamine could be associated with its antidepressant effects; however, it was accompanied with severe behavioral disruption. We also hypothesize that behavioral disruption produced by psychedelics objectively reflects their psychotomimetic-like actions.

27 November 2017 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
ANAgnieszka Nikiforuk
Agnieszka Nikiforuk
PKPredrag Kalaba
Predrag Kalaba
MIMarija Ilic
Marija Ilic
VKVolker Korz
Volker Korz
VDVladimir Dragačević
Vladimir Dragačević
GLGert Lubec
Gert Lubec
Reduced cognitive abilities are often characterized by an impairment of flexibility, i.e., the ability to switch from learned rules or categories that were important in certain contexts to different new modalities that rule the task. Drugs targeting the dopamine transporter (DAT) are widely used for their potential to enhance cognitive abilities. However, commercially available drugs are of limited specificity for DAT, blocking also noradrenaline and serotonine transporters, that can lead to unwanted side effects in healthy subjects. Therefore, we tested a newly synthetized compound (CE-123) with higher specificity for DAT in male rats in an attentional set-shifting task (ASST), that proves for cognitive flexibility and a 5-choice serial-reaction time task (5-CSRTT) assessing visuospatial attention and impulsivity. Treated rats at a dose of 0.3 and 1.0 but not 0.1 mg/kg bodyweight showed reduced extra-dimensional shifts in the ASST compared to controls indicating increased cognitive flexibility. Rats treated with R-Modafinil, a commercially available DAT inhibitor at a dose of 10 mg/kg bodyweight showed increased premature responses, an indicator of increased impulsivity, during a 10 s but not a 2.5, 5, or 7.5 s intertrial interval when compared to vehicle-treated rats in the 5-CSRTT. This was not found in rats treated with CE-123 at the same dose as for R-Modafinil. Visuospatial attention, except premature responses, did not differ between R-Modafinil and CE-123-treated rats and their respective controls. Thus, CE-123 increased cognitive flexibility with diminished impulsivity.

25 December 2014 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
RRRafał Ryguła
Rafał Ryguła
JGJoanna Golebiowska
Joanna Golebiowska
JKJakub Kregiel
Jakub Kregiel
MHMalgorzata Holuj
Malgorzata Holuj
PPPiotr Popik
Piotr Popik
Both valproic acid (VPA) and lithium (LI) are well-established treatments for therapy of intense and sustained mood shifts, which are characteristics of affective disorders, such as bipolar disorder (BP). As mood and cognitive judgment bias have been found to be strongly interrelated, the present study investigated, in an animal model, whether acute treatment with VPA or LI could affect cognitive judgment bias.

14 August 2014 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
RRRafał Ryguła
Rafał Ryguła
ESEwa Szczech
Ewa Szczech
JKJakub Kregiel
Jakub Kregiel
JGJoanna Golebiowska
Joanna Golebiowska
JKJakub Kubik
Jakub Kubik
PPPiotr Popik
Piotr Popik
Animal models of mania lack genuine cognitive parameters. The present gold standard of mania models, amphetamine-induced hyperlocomotion, is rather unspecific and does not necessarily target its cardinal symptoms. Therefore, alternative behavioral markers that are sensitive to stimulants are required.